Public Board of Directors papers 260123

EXECUTIVE SUMMARY

The Integrated Performance, Quality & Finance report presents a summary dashboard that provides an overview of performance.

Safe • One serious incident was reported in December. There were 5 incidents reported in month with the classification of moderate and 1 with the classification of major, details of which can be found on slide 8. All the incidents are still progressing through to full root cause analysis. No never events were reported in month. • There are 4 Trust level risks scored at 15+. Details of these can be found on slides 13 & 14. • Safer staffing numbers have met the required acuity levels to ensure appropriate levels of safety and care for our patients. Indicative staffing, in line with nursing establishments, is set to maintain a 1:6 nurse to patient ratio. On occasion this has been extended to 1:8 which is in line with recommended national staffing ratios. While we have seen an increase in patient safety incidents, following thematic review, these were not related to nurse staffing ratios. Responsive • Performance against the 62 day standard has reduced from November. The 62 day standard has not been met with a performance of 78.5%, subject to validation. The 62 day unvalidated upgrade performance is also below the standard with a performance of 78.1%. The internal 24 day target has not met the standard and is at 82.2%. All 62 and 24 day breaches are reviewed to ensure any delays are understood and plans can be implemented to mitigate any future delays. All 31 day targets and 18 week RTT standards have been achieved in December subject to validation. Performance against the CWT thresholds is constantly monitored. • After a peak in November referral numbers have reduced expectedly in December to a level consistent with the previous years’ total. The overall trend for the year continues to be significantly higher than the 21/22 average. • Activity levels are now monitored against agreed 22/23 plan. As at month 9 Chemotherapy deliveries and radiotherapy fractions along with non elective spells continue to be above plan whilst all other points of delivery are either on plan or tracking slightly below plan. Effective • There were 2 cases of C-Difficile, 5 cases of E-Coli, 2 cases of Klebsiella, 1 case of Pseudomonas and 2 cases of MSSA in December that were deemed attributable to the Trust. No lapses in care have been identified. • There were no cases of hospital acquired nosocomial Covid-19 infections in December. • Staff absence levels increased from November to a position of 6.22% against a target of 3.4%. • There continues to be improvement against the essential training threshold and there has also been continued improvement in the PDR performance which is now above the target of 84%. Well – Led • The trust is reporting a month 9 position of £75k surplus compared to a breakeven plan within the latest plan submission of an annual break even control total. • The month 9 I&E deficit is £13,418k, prior to adjusting for donated depreciation, charitably funded capital donations, donated grant income, donated consumables, transfers by absorption and impairments. • The cash balance is £146,303k. • Performance to month 9 is £11,742k below the proposed plan submitted to NHSE&I. The Paterson scheme is behind plan by £5.7m but still anticipated to meet plan by year end and conclude then. IFRS 16 leases, which are £3.8m behind plan, were anticipated to be contractually entered into by this point are yet to be committed. 27